Combined Use of a-GnRH and Intrauterine Levonorgestrel Releasing System in Treatment of Atypical Endometrial Hyperplasia in Women of Reproductive Age

Bibliography link: Pashov A.I., Sivova E.N., Metrinskiy Ya.Yu. Combined Use of a-GnRH and Intrauterine Levonorgestrel Releasing System in Treatment of Atypical Endometrial Hyperplasia in Women of Reproductive Age. Doctor.Ru. 2020; 19(1): 51–54. (in Russian) DOI: 10.31550/1727-2378-2020-19-1-51-54
4 February 09:39

Study Objective: to develop a patient-specific approach to management of patients of reproductive age with atypical endometrial hyperplasia (AEH).

Study Design: prospective study.

Materials and Methods. The study enrolled 50 patients with morphologically confirmed AEH. All patients were retrospectively allocated to two groups based on immunohistochemical marker expression values below and above threshold values — groups I and II, respectively. Group I comprised 39 (78.0 ± 5.9%) patients, whereas group II included 11 (22.0 ± 5.9%) patients. Median age in group I was 33 [27; 37] years old, in group II it was 30 [26; 33] years old. The treatment method was combined hormone therapy with a-GnRH (buserelin acetate 3.75mg) and levonorgestrel-containing intrauterine releasing system.

Study Results. Following therapy, 38 (97.4 ± 2.5%) out of 39 patients in group I had endometrium atrophy in 3 months, 1 (2.6 ± 2.5%) patient — in 6 months (p < 0.001);3 (27.3 ± 13.4%) patients in group II — in 3 months, and 8 (72.7 ± 13.4%) patients — in 6 months (p < 0.001). Where immunohistochemical marker expression values are below threshold values, a-GnRH (three times) + LNG-IUS regimen was prescribed, and where values are above threshold values — a-GnRH (six times) + LNG-IUS regimen.

No information on disease relapses in treated women is currently available. After treatment, 15 (30.0 ± 6.0%) women conceived.

Conclusion. Combined hormone therapy is efficient for treatment of AEH in fertile women wishing to have children.

Contribution: Pashov, A.I. — study concept and design, material collection and processing, article preparation, editing; Sivova, E.N. — study concept and design, material collection and processing, statistical data processing, article preparation; Metrinskiy, Ya.Yu. — article preparation, editing.

Conflict of interest: The authors declare that they do not have any conflict of interests.

Received: 25.12.2019
Accepted: 13.01.2020

A.I. Pashov (Corresponding author) — Immanuil Kant Baltic Federal University; 14 Alexander Nevskiy Str., Kaliningrad, Russian Federation 236016. eLIBRARY.RU SPIN: 5022-8272. E-mail:

E.N. Sivova — Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky of the Ministry of Health of Russia; 1 Partisan Zheleznyakov Str., Krasnoyarsk, Russian Federation 660022. eLIBRARY.RU SPIN: 3444-6028. E-mail:

Ya.Yu. Metrinskiy — Immanuil Kant Baltic Federal University; 14 Alexander Nevskiy Str., Kaliningrad, Russian Federation 236016. E-mail:

4 February 09:39
  1. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Malignancies in Russia in 2018 (morbidity and mortality). M.: Herzen Scientific Research Institute, Federal Research Centre for Radiology, Ministry of Health of Russia; 2019. 250 p. (in Russian)
  2. Saldivar J.S., ed. Cancer of the uterine endometrium. Advances and controversies. Intech Open; 2012. 182 p.
  3. Renaud M.C., Le T.; SOGC-GOC-SCC Policy and Practice Guidelines Committee; Special contributors. Epidemiology and investigations for suspected endometrial cancer. J. Obstet. Gynaecol. Can. 2013; 35(4): 380–1. DOI: 10.1016/S1701-2163(15)30970-1
  4. Novikova E.G., Tchoulkova O.V., Philatova Yu.V. Function-sparing treatment of premenopausal women with early stage endometrial carcinoma. Bulletin of N.N. Blokhin Russian Cancer Research Centre of the Russian Academy of Medical Science. 2009; 20(4): 80–3. (in Russian)
  5. Pashov A.I., Sivova E.N., Bukreev A.V., Fokina A.P. Immunohistochemical aspects of conservative combinaton treatment of atypical endometrial hyperplasia and well-differentiated adenocarcinoma of the endometrium in women of young age. Oncogynecology. 2015; 4: 29–33. (in Russian)
  6. Saprykina L.V., Dobrokhotova Yu.E., Litvinova N.A. Hyperplastic processes of endometrium: problems of ethiopathogenesis, clinics, diagnostics and treatment. General Medicine. 2011; 3: 4–8. (in Russian)
  7. Chernyshova A.L., Kolomiets L.A., Bochkareva N.V., Asadchikova O.N. Metabolic syndrome, interraction with endometrial carcinogenesis. Siberian Oncol. J. 2008; 5: 68–74. (in Russian)
  8. Chernukha G.E., Dumanovskaya M.R., Kogan E.A., Asaturova A.V., Faizullina N.M. New possibilities for the treatment of endometrial hyperplasia with natural micronized progesterone. Obstetrics and Gynecology. 2013; 10: 51–8. (in Russian)
  9. Gerasimov A.V., Tarkhov A.V., Babayantz E.V., Sasikyan V.T., Afanasieva N.A., Kulidzhanyan A.P. et al. Conservation therapy of atypical endometrial hyperplasia in women of reproductive age in Novosibirsk region. Siberian Oncol. J. 2008; suppl.1: 33. (in Russian)
  10. Kim M.K., Seong S.J. LNG-IUS treatment of non-atypical endometrial hyperplasia: can Pipelle endometrial sampling be an accurate method of follow-up evaluation? J. Gynecol. Oncol. 2013; 24(2): 103–4. DOI: 10.3802/jgo.2013.24.2.103
  11. Pashov A.I., Tskhay V.B., Ionouchene S.V. The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study. Gynecol. Endocrinol. 2012; 28(7): 559–61. DOI: 10.3109/09513590.2011.649813
  12. Hahnemann M.M., Alexander H.M., Cope N.J., Acheson N. Endometrial hyperplasia: a clinician’s review. Obstet. Gynecol. Reprod. Med. 2007; 17(6): 169–72. DOI: 10.1016/j.ogrm.2007.04.006
  13. Emons G., Beckmann M.W., Schmidt D., Mallmann P.; Uterus commission of the Gynecological Oncology Working Group (AGO). New WHO classification of endometrial hyperplasia. Geburtshilfe Frauenheilkd. 2015; 75(2): 135–6. DOI: 10.1055/s-0034-1396256
  14. Mittal K., Da Costa D. Endometrial hyperplasia and carcinoma in endo­metrial polyps: clinicopathologic and follow-up findings. Int. J. Gynecol. Pathol. 2008; 27(1): 45–8. DOI: 10.1097/pgp.0b013e318074fd60
  15. Goncharenko V.M., Beniuk V.A., Kalenska O.V., Demchenko O.M., Spivak M.Y., Bubnov R.V. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J. 2013; 4(1): 24. DOI: 10.1186/1878-5085-4-24
  16. Sanderson P.A., Critchley H.O.D., Williams A.R., Arends M.J., Saunders P.T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum. Reprod. Update. 2017; 23(2): 232–54. DOI: 10.1093/humupd/dmw042
  17. Stănescu A.D., Nistor I., Potecă A.G., Diţescu D., Comănescu M. Prognostic biomarkers in endometrial adenocarcinoma. Rom. J. Morphol. Embryol. 2014; 55(4): 1339–44.
  18. Zidan A.A., Hassan A.A., Seadah Sh.Sh.A., Ibrahim E.H., Attiah S.M. Selected immunohistochemical prognostic factors in endometrial hyperplasia versus carcinoma. J. Am. Sci. 2015; 11(4): 14–22.
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)